<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    MannKind Corporation

    MannKind Corporation

    At MannKind Corporation (NASDAQ: MNKD), we focus on the discovery, development and...

    At MannKind Corporation (NASDAQ: MNKD), we focu...

    Filing Type:    PU
    Madrigal Pharmaceuticals, Inc.

    Madrigal Pharmaceuticals, Inc.

    Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing no...

    Madrigal Pharmaceuticals is a clinical-stage bi...

    Filing Type:    PU
    Ourotech, Inc.

    Ourotech, Inc.

    A patient that is diagnosed with cancer today will have a genetic screen on their ...

    A patient that is diagnosed with cancer today w...

    Fundraising Status:    SD
    Filing Type:    CF
    Horizon Therapeutics Public Limited Company

    Horizon Therapeutics Public Limited Company

    Horizon is a biopharmaceutical company focused on researching, developing and comm...

    Horizon is a biopharmaceutical company focused ...

    Filing Type:    PU
    Caladrius Biosciences, Inc.

    Caladrius Biosciences, Inc.

    Caladrius is a clinical-stage biopharmaceutical company committed to the developme...

    Caladrius is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Ra Pharmaceuticals, Inc.

    Ra Pharmaceuticals, Inc.

    Ra PharmaÂŽ is a clinical-stage biopharmaceutical company using a proprietary pept...

    Ra PharmaÂŽ is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    H & G Science, Inc.

    H & G Science, Inc.

    H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...

    H&G Science aims to facilitate the safe and eff...

    Amount Raised:    $24,000.00
    Fundraising Status:    EC
    Filing Type:    CF
    Synthorx, Inc.

    Synthorx, Inc.

    Synthorx is a biotechnology company focused on prolonging and improving the lives ...

    Synthorx is a biotechnology company focused on ...

    Filing Type:    PU
    Atossa Genetics Inc.

    Atossa Genetics Inc.

    Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...

    Seattle-based Atossa Genetics (NASDAQ: ATOS) is...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.